Conflict of interest
Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data
Article first published online: 24 JAN 2013
© 2013 The Authors Journal of the European Academy of Dermatology and Venereology © 2013 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 3, pages 309–313, March 2014
How to Cite
Schaefer, I., Augustin, M., Spehr, C., Reusch, M. and Kornek, T. (2014), Prevalence and risk factors of actinic keratoses in Germany – analysis of multisource data. Journal of the European Academy of Dermatology and Venereology, 28: 309–313. doi: 10.1111/jdv.12102
M Augustin, and M. Reusch have been invited speakers of Leo Pharma and Almirall-Hermal, T. Kornek has been an invited speaker for Almirall-Hermal and has received honoraria and travel expenses from Leo Pharma. I. Schaefer and C. Spehr have no conflict of interest.
This study was supported by the German Society of Dermatology (DDG), the German Association of Office-Based Dermatologists (BVDD), Leo Pharma Germany and Almirall-Hermal, Germany.
- Issue published online: 19 FEB 2014
- Article first published online: 24 JAN 2013
- Manuscript Accepted: 21 DEC 2012
- Manuscript Received: 17 AUG 2012
- German Society of Dermatology (DDG)
- German Association of Office-Based Dermatologists (BVDD)
- Leo Pharma Germany
- Almirall-Hermal, Germany
In Europe, only few and inconsistent data on the prevalence and treatment of actinic keratoses (AK) are available.
To determine the prevalence of AK in Germany, to identify potential predictors and to estimate the number of AK cases treated in dermatological practices.
In a multiple-source approach, prevalence was assessed from whole-body examinations in a cohort of 90 800 employees and from nationwide statutory health insurance (SHI) data of 2008. The number of cases documented in dermatological offices was estimated from statistics of a SHI Physicians Association.
Standardized prevalence of AK from dermatological examinations was 2.7%; the rate increased with age (11.5% in the group 60–70 years) and was higher for men (3.9%) than for women (1.5%). Significant associations were also identified for skin phototype I, sunburns in childhood and solar lentigines. Vitiligo and a history of melanoma were also, but not significantly, associated with AK. In the SHI data analysis, standardized AK prevalence was 1.8%. Age-specific rates were below 1.5% up to 60 years and rose to 8.2% (13.2% in men) in the group 80–89 years. The prevalence from these large data sets – which is at the lower limit of studies from other countries – suggests about 1.7 million estimated AK cases in Germany.
In 2011, AK accounted for 8.3% of the hundred most frequently treated dermatological outpatient diagnoses. The proportion of AK cases has risen almost continuously over the last 10 years, compared to other dermatological conditions. Estimated annual number of AK cases documented by dermatologists in Germany is about 1.7 million.
Actinic keratosis is a frequent condition in higher age groups and more prevalent in men; a relevant need for health care is evident. Predictors and risk factors for AK are easy to identify in the population, which could also help to detect groups with special need for preventive measures.